JP7868025B2 - (s)-4-(4-(4-(((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-4-イル)オキシ)メチル)ベンジル)ピペラジン-1-イル)-3-フルオロベンゾニトリルを含む医薬組成物及びそれを使用する方法 - Google Patents

(s)-4-(4-(4-(((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-4-イル)オキシ)メチル)ベンジル)ピペラジン-1-イル)-3-フルオロベンゾニトリルを含む医薬組成物及びそれを使用する方法

Info

Publication number
JP7868025B2
JP7868025B2 JP2023501163A JP2023501163A JP7868025B2 JP 7868025 B2 JP7868025 B2 JP 7868025B2 JP 2023501163 A JP2023501163 A JP 2023501163A JP 2023501163 A JP2023501163 A JP 2023501163A JP 7868025 B2 JP7868025 B2 JP 7868025B2
Authority
JP
Japan
Prior art keywords
approximately
pharmaceutical composition
amount
compound
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023501163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533314A (ja
JP2023533314A5 (cg-RX-API-DMAC7.html
Inventor
アグラワル,アンジャリ
ケイ ミトラ,ビプロブ
グンワント トール,プラジワル
ヒギンズ-グルーバー,シャノン
アルモドバル ロドリゲス,ジェニファー
リウ,デミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2023533314A publication Critical patent/JP2023533314A/ja
Publication of JP2023533314A5 publication Critical patent/JP2023533314A5/ja
Application granted granted Critical
Publication of JP7868025B2 publication Critical patent/JP7868025B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023501163A 2020-07-07 2021-07-06 (s)-4-(4-(4-(((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-4-イル)オキシ)メチル)ベンジル)ピペラジン-1-イル)-3-フルオロベンゾニトリルを含む医薬組成物及びそれを使用する方法 Active JP7868025B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063048998P 2020-07-07 2020-07-07
US63/048,998 2020-07-07
PCT/US2021/040452 WO2022010854A1 (en) 2020-07-07 2021-07-06 Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)m ethyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same

Publications (3)

Publication Number Publication Date
JP2023533314A JP2023533314A (ja) 2023-08-02
JP2023533314A5 JP2023533314A5 (cg-RX-API-DMAC7.html) 2024-07-11
JP7868025B2 true JP7868025B2 (ja) 2026-06-01

Family

ID=77338767

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501163A Active JP7868025B2 (ja) 2020-07-07 2021-07-06 (s)-4-(4-(4-(((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-4-イル)オキシ)メチル)ベンジル)ピペラジン-1-イル)-3-フルオロベンゾニトリルを含む医薬組成物及びそれを使用する方法

Country Status (22)

Country Link
US (2) US12472176B2 (cg-RX-API-DMAC7.html)
EP (2) EP4178548B1 (cg-RX-API-DMAC7.html)
JP (1) JP7868025B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230035598A (cg-RX-API-DMAC7.html)
CN (1) CN115867261B (cg-RX-API-DMAC7.html)
AU (1) AU2021305052A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023000248A2 (cg-RX-API-DMAC7.html)
CA (1) CA3184460A1 (cg-RX-API-DMAC7.html)
DK (1) DK4178548T3 (cg-RX-API-DMAC7.html)
ES (2) ES2988714T3 (cg-RX-API-DMAC7.html)
FI (1) FI4178548T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241162T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068476T2 (cg-RX-API-DMAC7.html)
IL (1) IL299657A (cg-RX-API-DMAC7.html)
LT (1) LT4178548T (cg-RX-API-DMAC7.html)
MX (1) MX2023000292A (cg-RX-API-DMAC7.html)
PL (1) PL4178548T3 (cg-RX-API-DMAC7.html)
PT (1) PT4178548T (cg-RX-API-DMAC7.html)
RS (1) RS66027B1 (cg-RX-API-DMAC7.html)
SI (1) SI4178548T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400374T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022010854A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120004860A (zh) * 2020-07-20 2025-05-16 江苏恒瑞医药股份有限公司 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190008852A1 (en) 2017-07-10 2019-01-10 Celgene Corporation Antiproliferative compounds and methods of use thereof
WO2019223770A1 (zh) 2018-05-24 2019-11-28 江苏科技大学 一种可开闭月池挡板装置
WO2019226761A1 (en) 2018-05-23 2019-11-28 Celgene Corporation Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
PY0323128A (es) 2002-09-10 2012-12-03 Pharmacia Italia Spa Formulacion sólida que comprende un compuesto de indolina, útil en el tratamiento de trastornos relacionados con proteina de quinasas
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
AU2016213879B2 (en) 2009-05-19 2017-11-16 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
CA2772275A1 (en) 2009-09-18 2011-03-24 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
SMT201900071T1 (it) 2011-07-28 2019-02-28 Rigel Pharmaceuticals Inc Nuove formulazioni di (trimetossifenilammino)pirimidinile
TWI782395B (zh) 2016-01-08 2022-11-01 美商西建公司 抗增生化合物,及其醫藥組合物及用途
IL278854B2 (en) 2018-05-23 2026-01-01 Celgene Corp Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile
AU2020206692B2 (en) 2019-01-09 2025-03-27 Celgene Corporation Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190008852A1 (en) 2017-07-10 2019-01-10 Celgene Corporation Antiproliferative compounds and methods of use thereof
WO2019226761A1 (en) 2018-05-23 2019-11-28 Celgene Corporation Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use
WO2019223770A1 (zh) 2018-05-24 2019-11-28 江苏科技大学 一种可开闭月池挡板装置

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HANSEN,J.D. et al.,Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma,Journal of Medicinal Chemistry,2020年,Vol.63, No.13,pp.6648-6676,DOI:10.1021/acs.jmedchem.9b01928

Also Published As

Publication number Publication date
EP4438043A3 (en) 2024-11-27
EP4178548A1 (en) 2023-05-17
SI4178548T1 (sl) 2024-10-30
RS66027B1 (sr) 2024-11-29
DK4178548T3 (da) 2024-08-19
IL299657A (en) 2023-03-01
CN115867261A (zh) 2023-03-28
WO2022010854A1 (en) 2022-01-13
EP4438043C0 (en) 2026-02-25
JP2023533314A (ja) 2023-08-02
PL4178548T3 (pl) 2024-11-12
EP4178548B1 (en) 2024-07-24
HUE068476T2 (hu) 2024-12-28
LT4178548T (lt) 2024-09-25
MX2023000292A (es) 2023-02-09
PT4178548T (pt) 2024-10-22
SMT202400374T1 (it) 2024-11-15
ES2988714T3 (es) 2024-11-21
KR20230035598A (ko) 2023-03-14
US20260034122A1 (en) 2026-02-05
FI4178548T3 (fi) 2024-08-14
US20230270742A1 (en) 2023-08-31
AU2021305052A1 (en) 2023-02-09
EP4438043B1 (en) 2026-02-25
HRP20241162T1 (hr) 2024-11-22
CN115867261B (zh) 2025-05-23
CA3184460A1 (en) 2022-01-13
ES3068915T3 (en) 2026-06-03
EP4438043A2 (en) 2024-10-02
US12472176B2 (en) 2025-11-18
BR112023000248A2 (pt) 2023-01-31

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260327

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260421

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260520

R150 Certificate of patent or registration of utility model

Ref document number: 7868025

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150